Patents Assigned to INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 11932664
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: March 19, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Prodrugs of hydroxamate-based GCPII inhibitors
    Patent number: 11866394
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 9, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • 3?3?-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
    Patent number: 11766447
    Abstract: The present disclosure relates to 3?3?-cyclic dinucleotides having a carbocyclic nucleotide and derivatives that can modulate the activity of the STING adaptor protein.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: September 26, 2023
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Petra Brehova, Milan Dejmek, Radim Nencka, Ondrej Pav, Michal Sala
  • Mebendazole prodrugs with enhanced solubility and oral bioavailability
    Patent number: 11712435
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 1, 2023
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik, Lukas Tenora
  • Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
    Patent number: 11427590
    Abstract: Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer, are provided.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 30, 2022
    Assignees: The Johns Hopkins University, Institute of Organic Chemistry & Biochemistry
    Inventors: Barbara Slusher, Camilo Rojas, Ajit G. Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey
  • 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR
    Publication number: 20220160746
    Abstract: The present disclosure relates to 3?3?-cyclic dinucleotides having a carbocyclic nucleotide and derivatives that can modulate the activity of the STING adaptor protein.
    Type: Application
    Filed: March 4, 2020
    Publication date: May 26, 2022
    Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I
    Inventors: Gabriel BIRKUS, Petra BREHOVA, Milan DEJMEK, Radim NENCKA, Ondrej PAV, Michal SALA
  • 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF
    Publication number: 20220152078
    Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of Formula (I), the pharmaceutically acceptable salts, pharmaceutical composition and combinations of the substances and other medicaments or pharmaceuticals. The disclosure also relates to the compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases.
    Type: Application
    Filed: March 4, 2020
    Publication date: May 19, 2022
    Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel BIRKUS, Ondrej PAV, Ondrej KOSTOV, Petra BREHOVA, Martin Maxmilian KAISER, Ondrej SIMAK
  • 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF
    Publication number: 20220143061
    Abstract: The present disclosure relates to 3?3? cyclic phosphonate dinucleotides of general formula (I), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of the substances and other medicaments or pharmaceuticals. The disclosure also relates to compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases.
    Type: Application
    Filed: March 4, 2020
    Publication date: May 12, 2022
    Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel BIRKUS, Ondrej PAV, Petra BREHOVA, Ondrej SIMAK
  • 3?3?-cyclic dinucleotides
    Patent number: 11292812
    Abstract: The present invention relates to 3?3?-cyclic dinucleotides modified with a 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 5, 2022
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Ivan Rosenberg, Ondrej Simak
  • 2?3? cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
    Patent number: 11203610
    Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 21, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • 2?3?-cyclic dinucleotides
    Patent number: 11149052
    Abstract: The present disclosure relates to 2?3?-cyclic dinucleotides modified with a 2?- or 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: October 19, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Ivan Rosenberg, Ondrej Simak
  • Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
    Patent number: 11059775
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 13, 2021
    Assignees: The Johns Hopkins University, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • 3?3? cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
    Patent number: 10966999
    Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 6, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • DEVICE FOR PARALLEL OLIGOMER SYNTHESIS, METHOD OF PARALLEL OLIGOMER SYNTHESIS AND USE THEREOF
    Publication number: 20200384435
    Abstract: A device for parallel oligomer synthesis having a centrifuge with a plurality of reactor holders configured to retain reactors at an angle and a plurality of siphon based outflow holders are disclosed. A method of parallel solid-based peptide synthesis following the timing protocol of the device and a use of the device for parallel oligomer synthesis are also disclosed.
    Type: Application
    Filed: December 11, 2018
    Publication date: December 10, 2020
    Applicants: THE INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AV CR, SPYDER INSTITUTE PRAHA S.R.O.
    Inventors: Michal LEBL, Zuzana FLEGELOVA, Pavel PONCAR, Petr MUDRA, Ondrej PACES, Matyas KNOR, Michal BUZEK, Jiri SMRZ, Vit POKORNY, Vaclav PESEK
  • Quinazoline compounds
    Patent number: 10548898
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 4, 2020
    Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • 7-deazapurine nucleosides for therapeutic uses
    Patent number: 10294262
    Abstract: The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: May 21, 2019
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Aurelie Bourderioux, Michal Hocek, Petr Naus
  • Quinazoline compounds
    Patent number: 10206926
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 19, 2019
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE
    Publication number: 20190040036
    Abstract: Described herein are hypervalent iodine reagents.
    Type: Application
    Filed: August 6, 2018
    Publication date: February 7, 2019
    Applicants: ETH Zurich, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, V.V.I
    Inventors: Vaclav MATOUSEK, Petr BEIER, Antonio TOGNI
  • Hypervalent iodine CF2CF2X reagents and their use
    Patent number: 10040812
    Abstract: A hypervalent iodine of formula (I) or formula (II) wherein R is a nucleophile and a method for their production is described. Such compounds can be used for fluoroethylation of compounds carrying a reactive group. A preferred compound carrying a reactive group is cystein in any environment such as peptide targets.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: August 7, 2018
    Assignees: ETH ZURICH, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, V.V.I
    Inventors: Vaclav Matousek, Petr Beier, Antonio Togni
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 9988407
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik